FDA
-
-
-
-
-
-
-
Verve Therapeutics (VERV) Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
-
-
-
-
-
-
-
Stifel Names Top Picks in Biotechnology 2025 Outlook Note
-
-
-
-
-
-
-
Verve Therapeutics (VERV) Announces FDA Clearance of NDA for VERVE-101
-
-
-
-
-
-
-
Goldman Sachs Starts Verve Therapeutics (VERV) at Sell
-
-
-
-
-
-
-
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
-
-
-
-
322,206 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

